European Journal of Surgical Oncology

🎄✨Happy Holidays from the European Journal of Surgical Oncology ✨🎄 As the year comes to a close, we want to express our heartfelt gratitude to our readers, authors, reviewers, and the entire surgical oncology community for their continued support and contributions to the EJSO. Together, we’re shaping the future of cancer care by fostering innovation, collaboration, and excellence in research and education. Wishing you a joyful holiday season and a healthy, prosperous new year filled with exciting discoveries and progress. We look forward to continuing this journey with you in 2025! Warm regards, The EJSO Team Riccardo A. Audisio, Andreas Karakatsanis, Isacco Montroni Graeme Poston, John Whiting, Hassan Malik, Maggie Banys-Paluchowski, Marios Konstantinos Tasoulis MD, PhD, FEBS, FRCS, FACS, Pasithorn Suwanabol, harm rutten, Albert Wolthuis, Prof. dr. Barbara van Leeuwen, Giorgio Bogani, Volkert Wreesmann, Roberto Biffi, Nicola de' Liguori Carino, Roger Bagge Olofsson, Rachel Grossman, Olivier Glehen, Sylvie Bonvalot, Michael Shackcloth, Young-Woo Kim, Franco Roviello, Brian Birch, Pietro Mascagni, Denise Hilling, Dawn Aggett European Society of Surgical Oncology (ESSO), BASO ACS

This year, the European Journal of Surgical Oncology (EJSO) proudly celebrates its 50th anniversary. To commemorate this incredible milestone, we’re excited to release a special Presidential Edition! Here's to 50 years of progress and leadership in surgical oncology: #EJSO50 #SurgicalOncology #CancerCare

🌟 Publication highlight! 🌟 "Predictors of Early Recurrence of Oesophagogastric Adenocarcinoma After Neoadjuvant FLOT" Despite advancements in treatment, recurrence rates for oesophagogastric adenocarcinoma remain high, particularly following curative surgery. A new study by Abbienaya Dayanamby et al. dives into predictors of early recurrence in patients treated with neoadjuvant FLOT chemotherapy. 🔍 Key Findings: - 27.6% of patients experienced recurrence during follow-up, with 13.8% having early recurrence - Median survival after recurrence is 4.1 months - Independent risk factors for ER include extracapsular spread and ypN3 stage Understanding these predictors enables tailored follow-up strategies, such as more frequent imaging and targeted treatments for high-risk patients. Read the full article here: https://lnkd.in/dueek_3k Read the latest issue here: https://lnkd.in/eZH3ZNFZ Riccardo A. Audisio, Andreas Karakatsanis, Isacco Montroni Graeme Poston, John Whiting, Hassan Malik, Maggie Banys-Paluchowski, Marios Konstantinos Tasoulis MD, PhD, FEBS, FRCS, FACS, Pasithorn Suwanabol, harm rutten, Albert Wolthuis, Prof. dr. Barbara van Leeuwen, Giorgio Bogani, Volkert Wreesmann, Roberto Biffi, Nicola de' Liguori Carino, Roger Bagge Olofsson, Rachel Grossman, Olivier Glehen, Sylvie Bonvalot, Michael Shackcloth, Young-Woo Kim, Franco Roviello, Brian Birch, Pietro Mascagni, Denise Hilling, Dawn Aggett European Society of Surgical Oncology (ESSO), BASO ACS Abbienaya Dayanamby, Jakub Chmelo, Alexander Bradshaw, Alexander Phillips #CancerResearch #Oncology #Oesophaguscancer #EarlyRecurrence

The advancements in AI within surgical pathology are paving the way for transformative changes. Our recent article in the Elsevier European Journal of Surgical Oncology, authored by Jens Pahnke, Abderrahman Najjar, and Ofir H., delves into the current landscape and future prospects of AI in this field. The article explores the essential infrastructure required to support digital and computational pathology, shedding light on the hurdles impeding its widespread implementation in clinical practice. From AI applications in intraoperative and postoperative scenarios to addressing quality assessment concerns in slide digitization, the paper navigates through key challenges and opportunities. Additionally, the piece discusses emerging technologies like large language models, optical biopsies, and mass spectrometry imaging, offering a glimpse into the innovative tools shaping the future of surgical pathology. A heartfelt appreciation goes out to my colleagues for their important contributions to this work. I also want to thank to Pietro Mascagni for his kind referral. We anticipate the forthcoming challenges of 2025, we are committed to driving further advancements in AI and pathology for improved patient care and outcomes. https://lnkd.in/dmg8ep3g #SurgicalPathology #AI #MedicalAdvancements

Excited to share our recent publication in European Journal of Surgical Oncology on gemcitabine-cisplatin induction treatment in patients with locally advanced perihilar cholangiocarcinoma (LAPCCA). ‼️ Key findings: ❇️ Promising resection rate: 26% of patients (6/23), initially diagnosed as unresectable, underwent successful resections, supporting routine re-staging after three to six cycles of treatment. ❇️ Induction chemotherapy is a feasible approach for LAPCCA, paving the way for larger prospective studies to assess long-term oncological benefits. ❇️ This "proof-of-principle" study supports further exploration of neoadjuvant approaches in initially resectable patients. https://lnkd.in/eXsftEEb Many thanks to the team and patients who contributed to this study! Joris Erdmann Mélise Sickmann Geert Kazemier Marc Besselink Hanneke Wilmink Lynn Nooijen Mahsoem Ali Heinz-Josef Klümpen Babs Zonderhuis Rutger-Jan Swijnenburg

💫 Publication highlight 💫 As artificial intelligence (AI) continues to play an expanding role in surgery, it is important for surgeons to develop "AI literacy", building a solid foundation of knowledge to critically evaluate scientific literature, assess commercial product claims, and navigate the regulatory and legal frameworks surrounding AI development and implementation. Featured in our 𝗦𝗽𝗲𝗰𝗶𝗮𝗹 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻: 𝗔𝗜 & 𝗦𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 in the latest issue of the EJSO: "𝘈 𝘍𝘰𝘶𝘯𝘥𝘢𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘌𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘚𝘶𝘳𝘨𝘪𝘤𝘢𝘭 𝘈𝘳𝘵𝘪𝘧𝘪𝘤𝘪𝘢𝘭 𝘐𝘯𝘵𝘦𝘭𝘭𝘪𝘨𝘦𝘯𝘤𝘦 𝘓𝘪𝘵𝘦𝘳𝘢𝘵𝘶𝘳𝘦" by Daniel Hashimoto et al. This paper offers a structured framework to help surgeons effectively analyze manuscripts involving AI, advancing their ability to integrate AI solutions into clinical practice. 🔑 Key Takeaways: - 𝗙𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸𝘀 to evaluate AI manuscripts tailored for surgical applications. - Comprehensive 𝘁𝗲𝗿𝗺𝗶𝗻𝗼𝗹𝗼𝗴𝘆 and knowledge essentials for clinicians. - Recommendations for 𝗿𝗲𝗽𝗿𝗼𝗱𝘂𝗰𝗶𝗯𝗶𝗹𝗶𝘁𝘆, 𝘀𝗰𝗮𝗹𝗮𝗯𝗶𝗹𝗶𝘁𝘆, and practical implementation. - Strategies to address 𝗲𝘁𝗵𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝘁𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 in surgical AI. Dive into the full article: https://lnkd.in/gTjdzwen Access the latest issue: https://lnkd.in/eZH3ZNFZ How do you see AI transforming the future of surgery? Let us know your thoughts in the comments! 👇 Riccardo A. Audisio, Andreas Karakatsanis, Isacco Montroni Graeme Poston, John Whiting, Hassan Malik, Maggie Banys-Paluchowski, Marios Konstantinos Tasoulis MD, PhD, FEBS, FRCS, FACS, Pasithorn Suwanabol, harm rutten, Albert Wolthuis, Prof. dr. Barbara van Leeuwen, Giorgio Bogani, Volkert Wreesmann, Roberto Biffi, Nicola de' Liguori Carino, Roger Bagge Olofsson, Rachel Grossman, Olivier Glehen,Sylvie Bonvalot, Michael Shackcloth, Young-Woo Kim, Franco Roviello, Brian Birch, Denise Hilling, Dawn Aggett Daniel Hashimoto, Sai Koushik Sambasastry, Vivek Singh, Sruthi Kurada, Maria Altieri, Takuto Yoshida, Amin Madani, Matjaz Jogan European Society of Surgical Oncology (ESSO), BASO ACS #ArtificialIntelligence #SurgicalOncology #AIInSurgery #SurgicalAI

What is actually the value of "Letters to the editor" or "Comments on..."? Should we, as the scientific community, more critical or do we continue to view this as an easy way to boost publication rates? Look at our letter and decide..... #niekhugen, #mauriceloughrey, #europeanjournalofsurgicaloncology

I am pleased that the manuscript has now been published in the European Journal of Surgical Oncology.

Proud to announce that our paper has been published in the European Journal of Surgical Oncology. Robotic repeat liver surgery not only is safe and feasible, but also offers advantages over more ‘traditional’ laparoscopic and open methods. Link: https://lnkd.in/eig7a7sa Hereby, I want to express my gratitude to Mathieu D’Hondt for giving me the opportunity to collaborate on his research. Thank you as well to the co-authors of this paper for their contribution and making this publication possible - Edward Willems Celine De Meyere Isabelle Parmentier and Chris Verslype. This is also a nice completion of two years of surgical residency in az groeninge, Kortrijk. During this time, I had the chance to meet and work with inspiring people who not only deepened my knowledge and skills, but also taught me the important values in patient care. The next step: final year of surgical residency in abdominal surgery at UZ Leuven. Looking forward to it!

✨Proud to have co-authored the paper “Response prediction for neoadjuvant treatment in locally advanced rectal cancer patients-improvement in decision-making: a systematic review” published on the European Journal of Surgical Oncology (EJSO) with Luca Boldrini, Diepriye Charles-Davies and the entire team. 📖Our systematic review explores externally validated predictive models for response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer, aiming to enhance clinical decision-making through reliable predictive methods. 🏥 We hope this work contributes to better, data-driven treatment strategies in clinical practice. 🔗 Read the full article here: https://lnkd.in/gtxiJeKx #Radiology #Oncology #EJSO #RectalCancer